Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.

The firm will use the court-administered restructuring process to pursue strategic alternatives so it can continue developing vaccines and immunotherapies.

Immatics raised $175 million in a previous public stock offering earlier this year, and $110 million in a previous private stock offering in October 2022.

The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.

The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.

After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.

The new consortium, dubbed Thera4Care, launched with €25.3 million in EU government funding and 29 academic and industry partners.

The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.

In the HAELO trial, the firm will randomize 60 HAE patients to NTLA-2002 or placebo and compare the number of inflammatory attacks.

Astellas will make a $20 million equity investment in AviadoBio for the option to exclusively develop and commercialize AVB-1010.